{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:59Z","timestamp":1790963039190,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202218"],"award-info":[{"award-number":["82202218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07755-5","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:23:10Z","timestamp":1770596590000},"page":"3711-3719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["[68Ga]Ga-NY104 PET\/CT and [18F]FDG PET\/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial"],"prefix":"10.1007","volume":"53","author":[{"given":"Xinchun","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianshu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-4440","authenticated-orcid":false,"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"7755_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"7755_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","volume":"4","author":"RC Flanigan","year":"2003","unstructured":"Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4:385\u201390. https:\/\/doi.org\/10.1007\/s11864-003-0039-2.","journal-title":"Curr Treat Options Oncol"},{"key":"7755_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European association of urology guidelines on renal cell carcinoma: the 2025 update. Eur Urol. 2025;87:683\u201396. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.020.","journal-title":"Eur Urol"},{"key":"7755_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1148\/rg.336125110","volume":"33","author":"BP Brufau","year":"2013","unstructured":"Brufau BP, Cerqueda CS, Villalba LB, Izquierdo RS, Gonz\u00e1lez BM, Molina CN. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics. 2013;33:1691\u2013716. https:\/\/doi.org\/10.1148\/rg.336125110.","journal-title":"Radiographics"},{"key":"7755_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","volume":"12","author":"HY Wang","year":"2012","unstructured":"Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464\u201374. https:\/\/doi.org\/10.1102\/1470-7330.2012.0042.","journal-title":"Cancer Imaging"},{"key":"7755_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","volume":"48","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X, et al. 2-[(18)F]fdg pet\/ct parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:570\u20139. https:\/\/doi.org\/10.1007\/s00259-020-04996-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7755_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","volume":"58","author":"AB Stillebroer","year":"2010","unstructured":"Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2010.03.015.","journal-title":"Eur Urol"},{"key":"7755_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/s1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, et al. [(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277\u201387. https:\/\/doi.org\/10.1016\/s1470-2045(24)00402-9.","journal-title":"Lancet Oncol"},{"key":"7755_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/jco.2011.41.2445","volume":"31","author":"CR Divgi","year":"2013","unstructured":"Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187\u201394. https:\/\/doi.org\/10.1200\/jco.2011.41.2445.","journal-title":"J Clin Oncol"},{"key":"7755_CR10","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1007\/s00259-023-06248-7","volume":"50","author":"W Zhu","year":"2023","unstructured":"Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang H, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3116\u201325. https:\/\/doi.org\/10.1007\/s00259-023-06248-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7755_CR11","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1007\/s00259-024-06801-y","volume":"51","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, et al. Diagnostic efficacy of [(68)Ga]Ga-NY104 PET\/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2024;51:4127\u201333. https:\/\/doi.org\/10.1007\/s00259-024-06801-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7755_CR12","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1200\/jco.2003.04.073","volume":"21","author":"NS Majhail","year":"2003","unstructured":"Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995\u20134000. https:\/\/doi.org\/10.1200\/jco.2003.04.073.","journal-title":"J Clin Oncol"},{"key":"7755_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","volume":"82","author":"K De Man","year":"2022","unstructured":"De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, et al. 18F-PSMA-11 versus 68Ga-PSMA-11 positron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol. 2022;82:501\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.010.","journal-title":"Eur Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07755-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:26:16Z","timestamp":1777274776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07755-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7755"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07755-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wenjia Zhu and Li Huo are among the listed patent holders for [\n                      68\n                      Ga]Ga-NY104. No other potential conflicts of interest relevant to this article exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}